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ABSTRACT -Adrenoceptor antagonists differ in
their degree of partial agonism. In vitro assays have
provided information on ligand affinity, selectivity, and
intrinsic efficacy. However, the extent to which these
properties are manifest in vivo is less clear. Conscious
freely moving rats, instrumented for measurement of
heart rate (1; HR) and hindquarters vascular conduc-
tance (2; HVC) were used to measure receptor selec-
tivity and ligand efficacy in vivo. CGP 20712A caused a
dose-dependent decrease in basal HR (P<0.05,
ANOVA) at 5 doses between 6.7 and 670 g/kg (i.v.)
and shifted the dose-response curve for isoprenaline to
higher agonist concentrations without altering HVC
responses. In contrast, at doses of 67 g/kg (i.v.) and
above, ICI 118551 substantially reduced the HVC re-
sponse to isoprenaline without affecting HR responses.
ZD 7114, xamoterol, and bucindolol significantly in-
creased basal HR (HR: 12212, 12911, and
5911 beats/min, respectively; n6), whereas other
-blockers caused significant reductions (all at 2 mg/kg
i.v.). The agonist effects of xamoterol and ZD 7114
were equivalent to that of the highest dose of isopren-
aline. Bucindolol, however, significantly antagonized
the response to the highest doses isoprenaline. An
excellent correlation was obtained between in vivo and
in vitro measures of 1-adrenoceptor efficacy
(R20.93; P<0.0001).—Baker, J. G., Kemp, P., March,
J., Fretwell, L., Hill, S. J., Gardiner, S. M. Predicting in
vivo cardiovascular properties of -blockers from cel-
lular assays: a quantitative comparison of cellular and
cardiovascular pharmacological responses. FASEB J. 25,
4486–4497 (2011). www.fasebj.org
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Following their initial discovery in the 1960s (1),
-adrenoceptor antagonists (-blockers) have become
one of the most widely prescribed classes of drugs in
clinical practice (2, 3). They prevent endogenous cat-
echolamines from binding to -adrenoceptors, which,
in the heart, reduces the rate and force of contraction,
thereby reducing myocardial oxygen demand. In addi-
tion to their cardiac effects, beneficial effects on renin
release and, in some cases, sympathetic nerve activity
have meant that -blockers have been extremely valu-
able, and, indeed, in some conditions life-saving, in the
management of many cardiovascular disorders, includ-
ing angina, myocardial infarction, arrhythmias (includ-
ing perioperative arrhythmias), and hypertension (2,
4–9). Over the past decade, -blockers have been
proven to reduce mortality in patients with heart failure
by mechanisms that reduce catecholamine-driven myo-
cardial apoptosis, fibrosis, and remodeling (2, 5, 10). In
addition, -blockers are also used in the management
of glaucoma, portal hypertension, anxiety, migraine,
tremor, and hyperthyroidism (8, 11–16).
However, in clinical cardiovascular studies, -block-
ers do not seem to behave as a single class of drugs (2,
9, 17–23). For example, following the original reports
of the efficacy of -blockers in heart failure (24, 25), 6
-blockers have undergone trials in the management of
heart failure, 4 of which have been found to be helpful
and prolong life: bisoprolol (26), carvedilol (27), meto-
prolol (28), and nebivolol (29); one was found to be of
no benefit, bucindolol (30), and one (xamoterol)
actually increased mortality (31). In the only head-to-
head trial, carvedilol was found to be superior to
metoprolol in prolonging life, for the same degree of
-blockade (32). -Blockers differ in their receptor
selectivity (between 1 and 2-adrenoceptors; refs.
33–36) and in the extent of intrinsic sympathomi-
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metic activity (ISA; refs. 2, 10, 17, 20, 21). Interest-
ingly, -blockers with ISA (e.g., pindolol, xamoterol,
bucindolol) appear to be less effective in the treat-
ment of cardiovascular disease (10, 37, 38) and
migraine (14).
In pharmacological terms, -blockers with ISA are
partial agonists; thus, they block the stimulatory
effects of higher-efficacy agonists, such as adrenaline
(e.g., adrenaline-induced increases in heart rate), but
on their own, they actually stimulate a low-level
response (2, 39). Several studies have confirmed the
partial agonist effects of certain -blockers at the
cellular level in model cell systems (34, 39, 40–44).
Furthermore, some of these stimulatory actions of
-blockers have been observed in cardiac tissues (37,
38, 41, 45). The correlation between ISA in neonatal
rat cardiomyocytes and cardiovascular responses in
pithed rats was high, although that between adult
cardiac tissues and the whole animal was poor (17).
However, what is needed to reduce number, time,
and cost on animal experimentation is to know the
extent to which partial agonist effects of -blockers in
a model cell system are predictive of ISA in vivo in
intact animals.
In this study, we have compared the pharmacolog-
ical properties of a range of -blockers, including
those prescribed for heart failure, in an in vitro
Chinese hamster ovary (CHO) cell model to cardio-
vascular responses in vivo in conscious rats. Thus, the
correlation between the extent of partial agonism at
the 1-adenoceptor and selectivity between 1 and
2-adrenoceptors in vitro, and their effects on resting
and  agonist-induced heart rate (HR; 1 response)
and hindquarters vascular conductance (HVC; 2
response) in parasympathetically blocked conscious
rats has been examined. This has allowed us to test
the predictive power of the in vitro assays for in vivo
ISA and receptor selectivity in conscious animals.
MATERIALS AND METHODS
Materials
FCS was obtained from PAA Laboratories (Teddington, UK).
Microscint 20 scintillation fluid was obtained from PerkinEl-
mer (Shelton, CT, USA). 3H-CGP 12177, 3H-adenine, and
14C-cAMP were obtained from Amersham International (Lit-
tle Chalfont, UK). Bisoprolol, bucindolol, carvedilol, CGP
20712A, xamoterol and ZD7114 were from Tocris Life Sci-
ences (Avonmouth, UK). Fentanyl citrate was from Janssen-
Cilag (High-Wycombe, UK); medetomidine hydrochloride
(Domitor) and atipamezole hydrochloride (Antisedan) were
from Pfizer (Sandwich, UK); buprenorphine (Vetergesic)
was from Alstoe Animal Health (York, UK). Nebivolol
hydrochloride was from Sequoia Research Products (Pan-
gbourne, UK). All other reagents were from Sigma Chem-
icals (Poole, UK).
Constructs, cell lines, and cell culture
CHO K1 cells stably expressing either the human 1-adreno-
ceptor (at 1146 fmol/mg protein) or the human 2-adreno-
ceptor (at 466 fmol/mg protein) were used (33, 34). All cell
lines were grown in Dulbecco’s modified Eagle’s medium
nutrient mix F12 (DMEM/F12) containing 10% FCS and 2
mM l-glutamine in a 37°C humidified 5% CO2:95% air
atmosphere.
3H-CGP 12177 whole-cell binding
Cells were grown to confluence in white-sided tissue cul-
ture-treated 96-well view plates. 3H-CGP 12177 whole-cell
competition binding was performed as described previ-
ously (33) using 10 M propranolol to define nonspecific
binding and 3H-CGP 12177 in the range of 0.80–1.23 nM
(total volume 200 l/well). The KD value for
3H-CGP
12177 at the human 1 and 2 adrenoceptors is 0.42 and
0.17 nM, respectively (33). KD values for the competing
ligands were calculated from the IC50 values, as described
below.
3H-cAMP accumulation
Cells were grown to confluence in clear plastic tissue culture-
treated 24-well plates. Following 3H-adenine prelabeling, 3H-
cAMP accumulation in the wells was measured as described
previously (34). Ligands were incubated for 5 h. 3H-cAMP was
separated from other 3H-nucleotides by sequential Dowex
and alumina column chromatography, as described previ-
ously (46).
Animals and surgery
Adult, male, Sprague-Dawley rats (Charles River, Margate,
UK), weighing 300–350 g, were housed in groups in a
temperature-controlled (21–23°C) environment with a 12-h
light-dark cycle (lights on at 6 AM) and free access to food
(18% Protein Rodent Diet; Teklad Global, Bicester, UK) and
water for 7 d after arrival from the supplier before any
surgical intervention.
Surgery was performed in 2 stages under general anes-
thesia (fentanyl and medetomidine, 300 g/kg i.p. of each,
supplemented as required), with reversal of anesthesia and
postoperative analgesia provided by atipamezole (1 mg/kg
s.c.) and buprenorphine (0.02 mg/kg s.c.). At the first
surgical stage, a miniature pulsed Doppler flow probe was
sutured around the distal abdominal aorta to monitor
hindquarters hemodynamics. The wires from the probe
were taped and sutured at the nape of the neck, and the
animals were returned to the holding room. At the second
surgical stage, which took place at least 10 d after the
surgery for probe implantation, and following a satisfactory
inspection from the named veterinary surgeon, catheters
were implanted in the distal abdominal aorta via the caudal
artery [for arterial blood pressure (BP) monitoring and the
derivation of HR], and in the right jugular vein (for drug
administration). Three separate intravenous catheters were
placed in the jugular vein to enable concurrent adminis-
tration of different substances. At this stage, the wires from
the probe were soldered into a miniature plug (Microtech,
Boothwyn, PA, USA), which was mounted onto a custom-
designed harness worn by the rat. The catheters emerged
from the same point as the probe wires and were fed
through a protective spring secured to the harness and
attached to a counter-balanced pivot system. The arterial
catheter was connected to a fluid-filled swivel for overnight
infusion of heparinized (15 U/ml) saline to maintain
patency.
Experiments began 24 h after surgery for catheter
implantation, with animals fully conscious and unre-
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strained in home cages, with free access to food and water.
All procedures were carried out with approval of the
University of Nottingham Local Ethical Review Committee,
under Home Office Project and Personal License Author-
ity.
Cardiovascular recordings
Cardiovascular variables were recorded using a customized,
computer-based system [Instrument Development Engineer-
ing Evaluation (IDEEQ), Maastrich Instruments Bv, Maas-
trich, The Netherlands] connected to a transducer amplifier
(Gould, Eastlake, Ohio, USA) model 13–4615-50) and a
Doppler flowmeter (Crystal Biotech, Holliston, MA, USA)
VF-1 mainframe (pulse repetition frequency 125 kHz) was
fitted with high-velocity (HVPD-20) modules). Raw data were
sampled by IDEEQ every 2 ms, averaged and stored to disc
every cardiac cycle. HVC changes were calculated from the
changes in BP and Doppler shift.
Experimental protocol
In all experiments, atropine methyl nitrate (1 mg/kg/h; 0.4
ml/h) was infused continuously to remove any parasympa-
thetic influence on the control of HR. Starting 2 h after the
onset of the atropine infusion, rats were given 3-min infusions
(0.15 ml/min) of isoprenaline (4, 12, 40, and 120 ng/kg/
min) in ascending order separated by 20 min. At least 45
min after the last infusion of isoprenaline, a -adrenoceptor
antagonist or vehicle was given as an i.v. bolus (0.1 ml)
maintained by continuous infusion (0.4 ml/h), and the
isoprenaline infusions were repeated, starting 30 min there-
after. Experiments were run in 4 series, and within each
series, there was a contemporaneous control, and the antag-
onist doses (series 1 and 2) or different antagonists (series 3
and 4) were given in a randomized order.
Series 1
Rats (n6/group) were given isoprenaline before and after
administration of saline (0.1 ml bolus, 0.4 ml/h infusion) or
CGP 20712A at doses of 2, 6.7, 20, 67, 200, and 670 g/kg
bolus with 1, 3.3, 10, 33, 100, and 333 g/kg/h infusions,
respectively.
Series 2
The above experiment was repeated in groups of rats (n6/
group) given saline or ICI 118551 (volumes and doses as
above).
Series 3
Groups of rats (n6) were given isoprenaline before and
after administration of vehicle (saline, as above) or ZD 7114,
labetolol, xamoterol, pronethalol, bisoprolol, or acebutolol,
all at a dose of 2 mg/kg bolus, 1 mg/kg/h infusion. An
additional 2 groups of rats (n6/group) were given lower
doses of bisoprolol (20 g/kg bolus, 10 g/kg/h infusion
and 200 g/kg bolus, 100 g/kg/h infusion).
Series 4
Groups of rats (n6/group) were given isoprenaline before
and after administration of vehicle (5% propylene glycol, 2%
Tween 80 in sterile saline; 0.1 ml bolus, 0.4 ml/h infusion) or
nebivolol, carvedilol, or bucindolol, all at a dose of 2 mg/kg
bolus, 1 mg/kg/h infusion.
In vitro data analysis
Whole-cell binding
For competition binding, all data points on each binding
curve were performed in triplicate, and each 96-well plate
also contained 6 determinations of total and nonspecific
binding. In all cases in which a KD value is stated, the
competing ligand completely inhibited the specific binding
of 3H-CGP 12177.
A 1-site sigmoidal response curve was then fitted to the data
using GraphPad Prism 2.01 (GraphPad, San Diego, CA, USA)
and the IC50 was then determined as the concentration
required to inhibit 50% of the specific binding:
% uninhibited binding 100
(100 [A]
([A] IC50)
NS
where [A] is the concentration of the competing ligand, IC50
is the concentration at which half of the specific binding of
3H-CGP 12177 has been inhibited, and NS is the nonspecific
binding.
From the IC50 value and the known concentration of
3H-CGP 12177, a KD value (concentration at which half the
receptors are bound by the competing ligand) was calculated
using the equation:
KD 
IC50
1  ([3H-CGP 12177]/KD 3H-CGP 12177)
Functional assays: 3H-cAMP accumulation
Most agonist responses were best described by a 1-site sigmoi-
dal concentration response curve:
Response 
Emax  [A]
EC50  [A]
where Emax is the maximum response, [A] is the agonist
concentration, and EC50 is the concentration of agonist that
produces 50% of the maximal response.
The responses to bucindolol and carvedilol were, however,
best fitted to a 2-site concentration response:
% maximal stimulation 
[A]  N
([A]  EC150

[A]  (100  N)
([A]  EC250)
where N is the percentage of site 1, [A] is the concentration
of agonist, and EC150 and EC250 are the respective EC50
values for the two agonist sites.
A 10 M (maximal) isoprenaline concentration was
included in 2–3 wells in each plate for each separate
experiment for 3H-cAMP accumulation to allow agonist
responses to be expressed as a percentage of the isopren-
aline maximum for each experiment. All data are pre-
sented as means  se of triplicate determinations, and n in
the text refers to the number of separate experiments.
In vivo data analysis
Data were analyzed offline using IDEEQ software. Responses
to isoprenaline were measured as the difference between
steady-state values immediately before the isoprenaline infu-
sion and during the third minute of infusion. Changes in
baseline were measured as the difference between the control
values for the last dose of isoprenaline before, and the first
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dose of isoprenaline after, -adrenoceptor antagonist admin-
istration. Data were analyzed by t test or ANOVA with
Bonferroni correction as appropriate; P  0.05 was taken as
significant (GraphPad Prism 5.02).
RESULTS
Ligand affinity and selectivity: 3H-CGP 12177 whole-
cell binding
All ligands completely inhibited specific 3H-CGP 12177
binding to both the human 1- and human 2-adreno-
ceptors to yield KD values as shown in Table 1 and
Fig. 1. As expected, CGP 20712A was the most selective
1-adrenoceptor antagonist, and ICI 118551 was the most
selective 2-antagonist. Bisoprolol (36-fold), nebivolol
(23-fold) and xamoterol (20-fold) had some selectivity for
the 1-adrenoceptor, while pronethalol (4-fold), bucin-
dolol (5-fold), and carvedilol (6-fold) had marginal pref-
erence for the 2-adrenoceptor (Table 1).
Agonist efficacy: 3H-cAMP accumulation at the human
1-adrenoceptor
The degree of partial agonism for each of the ligands
was then established by comparing the maximum 3H-
cAMP accumulation response obtained with each li-
gand with that for the isoprenaline maximum response
stimulated in each experiment (Table 2 and Fig. 2).
Xamoterol, ZD 7114, and bucindolol were the most
efficacious partial agonists producing maximal re-
sponses that were 59, 49, and 49% respectively, of that
produced by isoprenaline. Most ligands stimulated a
concentration response that was best described by a
single component sigmoidal response curve. The re-
sponses to bucindolol and carvedilol, however, were
best described by a 2-component dose-response
curve. In both cases, the first component seen in
3H-cAMP accumulation yielded a log EC50 value
(9.23 or 9.22) that was very similar to the log KD
derived from ligand binding studies (Tables 1 and 2)
suggestive of partial agonist activation of the high-
TABLE 1. Log KD values obtained from
3H-CGP 12177 whole-cell binding studies in CHO cells
stably expressing either the human 1-adrenoceptor or the human 2-adrenoceptor
Ligand
1 2 Selectivity
Log KD n Log KD n 1 2
CGP 20712A 8.63  0.09 8 5.65  0.05 8 955
Bisoprolol 7.98  0.04 8 6.43  0.04 8 35.5
Nebivolol 8.79  0.09 8 7.42  0.04 8 23.4
Xamoterol 7.08  0.04 8 5.79  0.06 8 19.5
Acebutolol 6.57  0.02 8 5.70  0.03 8 7.4
ZD 7114 7.61  0.02 8 7.14  0.04 8 3.0
Labetolol 7.99  0.03 8 8.25  0.08 8 1.8
Pronethalol 6.67  0.03 8 7.27  0.02 8 4.0
Bucindolol 9.47  0.04 8 10.19  0.07 8 5.3
Carvedilol 9.26  0.05 8 10.06  0.06 8 6.3
ICI 118551 6.74  0.03 8 9.27  0.05 8 338
Values represent means  se for n separate experiments. Ligands are arranged in order of 1/2
selectivity.
Figure 1. Inhibition of 3H-CGP 12177-specific binding in whole CHO cells expressing human 1-adrenoceptor (A) and human
2-adrenoceptor (B). Nonspecific binding was determined by 10 M propranolol. Concentration of 3H-CGP 12177 present was
0.97 nM (A) and 1.11 nM (B). Data points are means  se of triplicate determinations. Results of single experiments shown are
representative of 8 separate experiments in each case.
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affinity catecholamine site. The higher concentration
of ligands required for the second component (log
EC50 values of 7.29 and 7.37 for bucindolol and
carvedilol, respectively) suggest secondary (low affin-
ity) site activation.
Effects of CGP 20712A and ICI 118551 on baseline
cardiovascular responses and responses to
isoprenaline in conscious rats (series 1 and 2)
CGP 20712A caused a significant decrease in basal HR at
doses of 20g/kgbolus and10g/kg/h infusion andabove
(Fig. 3, top panel, and Table 3). No change in basal HR was
seen following administration of ICI 118551 (Fig. 4, top
panel, and Table 3). CGP 20712A did not cause any change
in basal HVC (Fig. 3, bottom panel, and Table 3); however,
a reduction in HVC was seen at the highest dose of ICI
118551 (Fig. 4, bottom panel, and Table 3).
Isoprenaline infusions caused dose-dependent in-
creases in HR and HVC that were unaffected by saline
administration (Figs. 3–5). Administration of CGP
20712A caused a significant reduction in the HR re-
sponse to isoprenaline at doses of 20 g/kg bolus and
10 g/kg/h infusion and above, but had no significant
effect on the HVC responses to isoprenaline at any dose
tested (Fig. 3 and Table 3). In contrast, at doses of 67
g/kg bolus and 33 g/kg/h infusion and above, ICI
118551 substantially reduced the HVC response to
isoprenaline without affecting the HR responses (Fig. 4
and Table 3). This confirms that the HR response
observed is predominantly occurring via the 1-adre-
noceptor, whereas the HVC response is predominantly
via the 2-adrenoceptor.
For comparison, we also evaluated the cardiovascular
responses to bisoprolol, which demonstrated the best
selectivity between 1 and 2 adrenoceptors among the
TABLE 2. Log EC50 values and percentage isoprenaline maximal responses obtained from
3H-cAMP accumulation assays in cells expressing the human 1-adrenoceptor
Ligand Log EC50 cAMP, 1 Isomax (%) n
Xamoterol 8.06  0.10 59.3  2.3 5
ZD 7114 8.37  0.05 49.1  4.1 6
Bucindolol 49.0  2.8 6
Site 1 9.23  0.04, 64.7  2.5%
Site 2 7.29  0.20
Pronethalol 7.34  0.04 28.6  2.8 6
Acebutolol 7.00  0.05 20.0  2.2 7
Labetolol 6.96  0.07 17.5  2.1 6
Carvedilol 14.8  1.0 11
Site 1 9.22  0.06, 42.6  1.1%
Site 2 7.37  0.05
Nebivolol 8.80  0.04 2.28  0.28 7
Bisoprolol No response 0 3
ICI 118551 No response 0 3
CGP 20712A No response 0 3
Values are presented as means  se of n separate determinations. Values provided for isoprenaline
maximum (Isomax) response for bucindolol and carvedilol are for response at the maximum obtained,
i.e., site 1  site 2. Ligands are ranked in order of partial agonism.
Figure 2. 3H-cAMP accumulation in CHO cells expressing the human 1-adrenoceptor in response to xamoterol, ZD 7114,
pronethalol, acebutolol and bisoprolol (A) and bucindolol (B). Bars represent basal 3H-cAMP accumulation and that in
response to 10 M isoprenaline. Data points are means se of triplicate determinations. Results are representative of 3 (A) and
6 (B) separate experiments.
4490 Vol. 25 December 2011 BAKER ET AL.The FASEB Journal  www.fasebj.org
clinically used -blockers in cellular systems (Table 1).
Given the lower affinity of bisoprolol for the human
1-adrenoceptor (as compared to CGP 20712A), we
extended the concentration of bisoprolol to 2000
g/kg bolus and 1000 g/kg/h infusion. Bisoprolol
produced a concentration-dependent decrease in both
basal HR (Table 3) and isoprenaline-induced tachycar-
dia (Fig. 5). However, at a dose of 2000 g/kg bolus
and 1000 g/kg/h infusion, there was a significant
basal vasoconstriction (Table 3) and an inhibition of
isoprenaline-stimulated HVC responses (Fig. 5), indic-
ative of 2-adrenoceptor antagonism.
Figure 3. Absolute values for HR (top panel) and HVC (bottom panel) in conscious, atropine-treated, freely moving rats in
response to isoprenaline (at 0, 4, 12, 40, and 120 ng/kg/min) before and after administration of CGP 20712A at doses of 0–670
g/kg bolus, 0–333 g/kg/h infusion. Values (meanse; n6) were measured at baseline (B; i.e., in the absence of
isoprenaline) and at the end of 3-min infusions of isoprenaline.
TABLE 3. Changes in baseline cardiovascular variables following administration of CGP 20712A, ICI 118551, and bisoprolol
Antagonist and variable
Antagonist concentration (g/kg)
0 2 6.7 20 67 200 670 2000
CGP 20712A
	HR (beats/min) 1  3 22  10 12  7 42  7* 56  6* 48  3* 69  4*
	MAP (mmHg) 3  2 0  2 2  2 3  1 2  3 3  4 5  3
	HVC (%) 8  6 3  4 8  3 15  5 16  5 12  5 19  3
ICI 118551
	HR (beats/min) 17  6 27  5 15  5 14  11 24  11 27  6 32  6
	MAP (mmHg) 3  1 1  2 4  3 0  2 5  2 5  6 13  4
	HVC (%) 4  6 8  3 12  5 8  3 19  3 17  6 30  6*
Bisoprolol
	HR (beats/min) 14  9 45  5* 64  9* 70  17*
	MAP (mmHg) 2  3 2  2 2  3 5  2
	HVC (%) 3  2 11  4 14  6 23  5*
Values are calculated as the difference (meanse) between the values immediately before the last dose of isoprenaline prior to antagonist
administration, and the values immediately before the first dose of isoprenaline after antagonist administration; n  6/group. HR, heart rate,
MAP, mean arterial pressure, HVC, hindquarters vascular conductance. *P  0.05 vs. 0 dose; ANOVA.
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Selectivity and efficacy of -blockers in conscious rats
(series 3 and 4)
The cardiovascular studies were then extended to li-
gands that exhibited partial agonist effects in measure-
ments of cAMP in transfected cells. Given the poor
solubility of carvedilol, nebivolol, and bucindolol, these
ligands were dissolved in 5% propylene glycol and 2%
Tween 80 in sterile saline, rather than saline, and this
was used as the vehicle control in series 4 (see Fig. 7).
Neither saline (series 3) nor vehicle (series 4) had any
significant effect on baseline cardiovascular variables.
Changes in baseline cardiovascular variables follow-
ing administration of the chosen -adrenoceptor antag-
onists at a dose of 2 mg/kg bolus and 1 mg/kg/h
infusion are shown in Table 4. ZD 7114, xamoterol, and
bucindolol caused significant increases in basal HR,
whereas labetolol, bisoprolol, carvedilol, and nebivolol
all caused significant reductions in basal HR (Table 4
and Fig. 6). In the case of both xamoterol and ZD 7114,
the agonist effect was equivalent to that of the highest
dose of isoprenaline, and as a consequence, no antag-
onism of isoprenaline-stimulated increases in HR was
apparent (Fig. 6). Bucindolol (Fig. 7) exhibited a lower
agonist effect than xamoterol and ZD 7114, and it was
able to significantly antagonise the response to the
highest doses isoprenaline in a manner expected for a
partial agonist (Fig. 7). Significant antagonism of the
HR responses to all four doses of isoprenaline were
obtained with acebutolol pronethalol, labetolol, carve-
dilol, and nebivolol (Figs. 6 and 7).
Administration of labetolol, pronethalol, and bucin-
dolol caused increases in HVC which, in the case of
labetolol and bucindolol, were accompanied by falls in
blood pressure. Interestingly, carvedilol caused a reduc-
tion in blood pressure, which was not accompanied by
an increase in HVC, possibly indicative of vasodilatation
in other vascular beds.
All drugs tested inhibited the HVC responses to the 2
highest doses of isoprenaline, with the exception of
nebivolol (which only inhibited the highest dose of
isoprenaline) and bucindolol (Figs. 6 and 7). In the
case of bucindolol, there was a marked partial agonist
effect on HVC, and this compound was also only able to
attenuate the response to the highest dose of isopren-
aline (Figs. 6 and 7).
A comparison of the in vitro efficacy of the different
-blockers (i.e., the size of the response as compared to
the isoprenaline maximum responses, taken from Ta-
ble 1) and their ISA activity as judged by basal HR
effects in vivo is shown in Fig. 8. The excellent correla-
tion between the two (R20.93; P0.0001) is striking.
Clearly, the partial agonism seen on cAMP accumula-
tion in transfected CHO cells will depend on the level
Figure 4. Absolute values for HR (top panel) and HVC (bottom panel) in conscious, atropine-treated, freely moving rats in
response to isoprenaline (at 0, 4, 12, 40, and 120 ng/kg/min) before and after administration of ICI 118551 at doses of 0–670
g/kg bolus and 0–333 g/kg/h infusion. Values (meansse; n6) were measured at baseline (B; i.e., in the absence of
isoprenaline) and at the end of 3-min infusions of isoprenaline.
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of receptor expression, and it is notable that the
expression level used in this study is relatively high
(1146 fmol/mg protein). However, it is also clear from
the in vivo studies that it is only ligands exhibiting

20% of the maximal isoprenaline response in this cell
line that have detectable ISA at the level of HR re-
sponses in the conscious rat (Fig. 8).
DISCUSSION
-Blockers have been used in the management of
cardiovascular disorders with great success for several
decades. However the results from more recent heart
failure trials have suggested that not all -blockers are
the same, with some being helpful and prolonging life,
while others are detrimental. Recent evidence from cell
studies has suggested that many -blockers actually
stimulate agonist responses but that the degree of
stimulation (efficacy) varies among -blockers. The
primary aim of this study was, therefore, to examine the
correlation between agonist actions of -blockers ob-
served in a model cell system with any ISA seen in a
whole animal.
In keeping with previous studies (33, 35, 47, 48),
CGP 20712A was a very selective 1-adrenoceptor an-
tagonist in the CHO cell system and had high affinity
and high selectivity for the human 1-adrenoceptor
(955 fold 1-selective), and ICI 118551 was confirmed
to be a high-affinity highly 2-selective ligand (388 fold
2-selective). These compounds were, therefore, used
to determine the contribution of 1- and 2-adreno-
ceptors to the basal and isoprenaline-induced changes
in rat HR and HVC. Alone, CGP 20712A lowered HR
below basal. It also inhibited the isoprenaline-induced
tachycardia but had no effect on either resting HVC or
isoprenaline-induced hindquarters vasodilatation. In
contrast, ICI 118551 had no effect on HR (either basal
or isoprenaline-induced) but did reduce HVC (basal
and isoprenaline-stimulated). From these studies, it is
possible to conclude that in the conscious rat model
used here, the changes in HR were predominantly
mediated by 1-adrenoceptors and the changes in HVC
via the 2-adrenoceptor.
To provide a comparison for the in vivo experiments,
the degree of partial agonism was determined for each
ligand in the CHO cell line expressing the human
1-adrenoceptor. From this, it can be seen that the
ligands with the highest degree of partial agonism
(biggest cAMP stimulation) were xamoterol and bucin-
dolol, with several of the ligands having no basal cAMP
stimulatory effect (Table 2), most notably bisoprolol.
When examined in vivo, several ligands stimulated
substantial increases in basal HR (Table 4 and Fig. 8),
and the rank order of the compounds was exactly the
same as that obtained from measurements of basal
cAMP accumulation (Fig. 8). Interestingly, this is in
keeping with previous studies in human myocardium,
both normal and failing human heart (37, 38, 45) and
rats (17). It has been previously proposed (38, 39) that
the cellular basis for ISA observed in animals occurs
from cAMP-driven partial agonism. Clinically, the drugs
with highest ISA, xamoterol (31) and bucindolol (30),
were the ones found to be nonbeneficial/detrimental
in clinical heart failure studies, whereas the ligands with
TABLE 4. Changes in baseline cardiovascular variables
following administration of saline, vehicle, and different -blockers
(series 3 and 4)
Ligand
	HR, 1
(beats/min) 	BP (mmHg) 	HVC, 2 (%)
Saline 14  9 2  3 3  2
Xamoterol 129  11* 1  3 12  8
ZD 7114 122  12* 5  3 20  6*
Pronethalol 23  10 1  2 33  12*
Acebutolol 5  6 1  2 9  5
Labetolol 26  9* 19  2* 72  12*
Bisoprolol 70  17* 5  2 23  5*
Vehicle 10  8 1  2 3  11
Bucindolol 59  11* 19  2* 51  10*
Carvedilol 54  10* 17  3* 13  5
Nebivolol 55  13* 4  2 3  7
Values are calculated as the difference (meanse) between the
values immediately before the last dose of isoprenaline prior to
antagonist administration, and the values immediately before the first
dose of isoprenaline after antagonist administration; n  6 group.
-Adrenoceptor antagonists were all given at a dose of 2 mg/kg bolus
followed by 1 mg/kg/h infusion. *P  0.05; paired t test.
Figure 5. Absolute values for HR (top panel) and HVC
(bottom panel) in conscious, atropine-treated, freely moving
rats in response to isoprenaline (at 0, 4, 12, 40, 120 ng/kg/
min) following administration of bisoprolol at doses of
0–2000 g/kg bolus, 0–1000 g/kg/h infusion. Values
(meansse; n6) were measured at baseline (B; i.e., in the
absence of isoprenaline) and at the end of 3-min infusions of
isoprenaline.
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little agonist efficacy were life-prolonging: carvedilol
(27), nebivolol (29), and bisoprolol (26).
Several -blockers (especially propranolol) have
been shown to have biased signaling at the human
2-adrenoceptor (i.e., they are inverse agonists on one
pathway, e.g., cAMP, while stimulating agonist actions
on another pathway, e.g., MAP kinase; refs. 43, 49). This
has also been demonstrated for propranolol at the
1-adrenoceptor (50, 51). Interestingly, at the 1-
adrenoceptor, carvedilol and bucindolol have been
shown to activate both cAMP and MAP kinase pathways
(51). However, as carvedilol was found to be beneficial
in heart failure (27), whereas bucindolol was not (30),
it is difficult to know what role MAP kinase signaling
has in a clinical context. It will be interesting to
examine how the effects of MAP kinase activity corre-
late with longer-term physiological cardiovascular re-
sponses and potential pathological changes, e.g., re-
modeling and cell proliferation in heart failure.
The 1-adrenoceptor has been reported to exist in at
least two active agonist conformations or sites: the
catecholamine site, at which isoprenaline and many
agonists act and where many -blockers bind with high
affinity, and a secondary site, where certain -blockers
can elicit agonist responses at higher concentration
(52–55). In cell-based assays, xamoterol, ZD 7114,
labetolol, and acebutolol have previously been shown
to have their agonist action via the catecholamine site,
while the agonist action of carvedilol was via the
secondary site (42, 44). Bucindolol has been shown to
be a partial agonist at the human 1-adrenoceptor in
human myocardium (37, 45, 56), and this partial
agonist action has been reported to occur via the
secondary site of the human 1-adrenoceptor (45).
In this study, bucindolol stimulated an increase in
3H-cAMP that was best described by a 2-component
concentration-response curve. The most likely explana-
tion for this is that the first major (high-affinity)
component is occurring via the catecholamine site and
the second (low-affinity) component via the secondary
site on the receptor. This is similar to other previously
reported ligands, e.g., pindolol, where a 2-component
response is seen in cell-based assays (34, 42, 57), and
the ISA response in human myocardium has been
shown to be via the secondary site (41). In the present
study, the 3H-cAMP response to carvedilol was also best
Figure 6. Absolute values for HR (top panel) and HVC (bottom panel) in conscious, atropine-treated, freely moving rats in
response to isoprenaline (at 0, 4, 12, 40, and 120 ng/kg/min) following administration of saline and several different -blockers
(2 mg/kg bolus, 1 mg/kg/h infusion). Values (meansse; n6) were measured at baseline (B; i.e., in the absence of
isoprenaline) and at the end of 3-min infusions of isoprenaline.
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described by a 2-component response, although here
the secondary site appeared to be the more abundant.
Taken together, these data suggest that ISA can occur
from partial agonism at either the catecholamine site
(xamoterol, ZD 7114) or via the secondary site (bucin-
dolol). Furthermore, the clinical effectiveness of the
drugs used in heart failure also appears to be inde-
pendent of the site activated by the ligand. Thus,
bucindolol (not helpful clinically in heart failure; ref.
30) and carvedilol (beneficial in heart failure; ref. 27)
can both access both sites of the 1-adrenoceptor. The
agonist action of xamoterol (catecholamine site) is
detrimental in humans (31), as is that of bucindolol
[secondary site (45)]. Therefore, it appears that it is the
overall amount of agonism/ISA that is detrimental in
humans, not the site on the 1-adrenoceptor at which
it occurs.
The selectivity of -blockers was also examined in
both the cellular model and in the rats. Unlike CGP
20712A, bisoprolol, nebivolol, and xamoterol were rel-
atively poor 1-adrenoceptor-selective ligands in the
CHO cell studies, in keeping with previous selectivity
studies (33, 35, 36, 47, 48). CGP 20712A and ICI 118551
clearly demonstrated marked selectivity in the rat stud-
ies. Interestingly, bisoprolol (an inverse agonist at the
human 2-adrenoceptor; ref. 43), one of the most
1-selective drugs that are clinically available, was also
shown to have relatively poor selectivity in the rat
cardiovascular studies, in as much as bisoprolol caused
a reduction in isoprenaline-stimulated HR (1) but
also a reduction in HVC (2) at the highest dose tested.
When this was extended to the other -blockers, it
can be seen that the other -blockers had effects on the
both the isoprenaline-stimulated HR response (1)
and the hindquarters 2-response and that this was
most marked for the least selective (or even slightly
2-selective) ligands (e.g., bucindolol, carvedilol). The
lack of selectivity among clinically used -blockers, seen
in the CHO cell model system, is, therefore, also seen in
the conscious rat model. Given that it is possible for a
1-selective compound to be devoid of 2 effects (i.e.,
CGP 20712A), there is clearly a need for the develop-
ment of -blockers with improved selectivity for clinical
use.
CONCLUSIONS
The degree of partial agonism seen in a cell-based
cAMP assay correlated very well with the observed
degree of ISA in vivo, as judged by changes in basal HR
in conscious rats. The cell-based assay is, therefore,
highly predictive for the level of clinically relevant ISA
seen in animals. ISA can occur from stimulation of
either the catecholamine site or the secondary site of
the receptor or both; however, the site of partial agonist
action does not matter for clinical effectiveness in heart
failure studies—the ligands with the least overall stim-
Figure 8. Correlation plot of the efficacy of -blockers for the
in vitro vs. in vivo data. In vitro efficacy is the maximum
3H-cAMP accumulation response (given as percentage of the
maximum response to isoprenaline) in cells expressing the
human 1-adrenoceptor. The in vivo efficacy is the change in
HR (beats/min) in response to the administration of
the -blocker alone in conscious freely moving rats (ISA).
Ligands are at 2 mg/kg bolus, 1 mg/kg/h infusion except for
CGP 20712A and ICI 118551, which were at 670 g/kg bolus,
333 g/kg/h infusion. For ligands with a 2-component
3H-cAMP accumulation response (bucindolol and carve-
dilol), efficacy is given as the maximum efficacy obtained for
that ligand (i.e., includes response at site 1 plus that at site 2).
Line is that of best fit through all the ligands.
Figure 7. Absolute values for HR (top panel) and HVC
(bottom panel) in conscious, atropine-treated, freely moving
rats in response to isoprenaline (at 0, 4, 12, 40, and 120
ng/kg/min) following administration of vehicle (5% propyl-
ene glycol, 2% Tween 80 in saline), bucindolol, carvedilol,
and nebivolol (2 mg/kg bolus, 1 mg/kg/h infusion). Values
(meansse; n6) were measured at baseline (B; i.e., in the
absence of isoprenaline) and at the end of 3-min infusions of
isoprenaline.
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ulatory activity are those most useful in heart failure.
Many clinically used -blockers have been previously
shown to have poor selectivity between the 1- and
2-adrenoceptors in cell-based assays. The in vivo assay
used here (i.e., parasympathetically blocked conscious
rats instrumented for measuring isoprenaline-induced
tachycardia and hindquarters vasodilatation) can also
clearly demonstrate 1- and 2-selectivity and identify
compounds with good (e.g., CGP 20712A and ICI
118551) and poor selectivity (bisoprolol). Thus, in vitro
3H-CGP 12177 whole-cell binding and 3H-cAMP accu-
mulations assays are good predictors of the ISA (partial
agonism) and ligand selectivity as seen in whole
animals.
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